Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study by Ren, Zhenggang, Prof, Xu, Jianming, Prof, Bai, Yuxian, Prof, Xu, Aibing, Prof, Cang, Shundong, Prof, Du, Chengyou, Prof, Li, Qiu, Prof, Lu, Yinying, Prof, Chen, Yajin, Prof, Guo, Yabing, Prof, Chen, Zhendong, Prof, Liu, Baorui, Prof, Jia, Weidong, Prof, Wu, Jian, Prof, Wang, Junye, Prof, Shao, Guoliang, Prof, Zhang, Bixiang, Prof, Shan, Yunfeng, Prof, Meng, Zhiqiang, Prof, Wu, Jianbing, Prof, Gu, Shanzhi, Prof, Yang, Wei, Prof, Liu, Chao, Prof, Shi, Xuetao, Prof, Gao, Zhenyuan, Prof, Yin, Tao, Prof, Cui, Jiuwei, Prof, Huang, Ming, Prof, Xing, Baocai, Prof, Mao, Yilei, Prof, Teng, Gaojun, Prof, Qin, Yanru, Prof, Wang, Jinhai, Prof, Xia, Feng, Prof, Yin, Guowen, Prof, Yang, Yong, MD, Chen, Mingxia, MD, Wang, Yan, MD, Zhou, Hui, MD, Fan, Jia, Prof

Get full text